Ekso Bionics (EKSO) 10-Q 9 Nov 16 2016 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Nov. 02, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Entity Registrant Name	EKSO BIONICS HOLDINGS, INC.
Entity Central Index Key	1,549,084
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	EKSO
Entity Common Stock, Shares Outstanding		21,880,959

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash	$ 12,800	$ 19,552
Accounts receivable, net	2,200	2,069
Inventories, net	1,915	1,056
Note receivable, current	34	0
Prepaid expenses and other current assets	533	436
Deferred cost of revenue, current	92	2,088
Total current assets	17,574	25,201
Property and equipment, net	2,561	2,625
Note receivable	41	0
Deferred cost of revenue	0	2,502
Intangible assets, net	1,162	1,584
Goodwill	189	189
Other assets	94	97
Total assets	21,621	32,198
Current liabilities:
Accounts payable	1,359	2,694
Accrued liabilities	2,982	1,885
Deferred revenues, current	1,098	3,960
Capital lease obligation, current	67	80
Total current liabilities	5,506	8,619
Deferred revenues	822	4,613
Warrant liability	6,165	9,195
Contingent consideration liability	768	768
Other non-current liabilities	132	195
Total liabilities	13,393	23,390
Commitments and contingencies (Note 14)
Stockholders' equity:
Convertible preferred stock, $0.001 par value; 10,000 shares authorized at September 30, 2016 and December 31, 2015; 0 and 13 shares outstanding at September 30, 2016 and December 31, 2015, respectively	0	0
Common stock, $0.001 par value; 71,429 shares authorized at September 30, 2016 and December 31, 2015; 21,393 and 15,027 shares outstanding at September 30, 2016 and December 31, 2015, respectively	21	15
Additional paid-in capital	117,498	100,184
Accumulated other comprehensive loss	(7)	(1)
Accumulated deficit	(109,284)	(91,390)
Total stockholders' equity	8,228	8,808
Total liabilities and stockholders' equity	$ 21,621	$ 32,198

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets [Parenthetical] - $ / shares shares in Thousands	Sep. 30, 2016	Dec. 31, 2015
Convertible Preferred stock, par value per share	$ 0.001	$ 0.001
Convertible Preferred stock, shares authorized	10,000	10,000
Convertible Preferred stock, shares issued	0	13
Convertible Preferred stock, shares outstanding	0	13
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	71,429	71,429
Common Stock, Shares, Issued	21,393	15,027
Common Stock, Shares, Outstanding	21,393	15,027

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenue:
Device and related	$ 1,495	$ 1,095	$ 11,003	$ 3,128
Engineering services	101	1,820	631	3,590
Total revenue	1,596	2,915	11,634	6,718
Cost of revenue:
Device and related	1,123	1,095	9,078	2,863
Engineering services	70	1,352	452	2,482
Total cost of revenue	1,193	2,447	9,530	5,345
Gross profit	403	468	2,104	1,373
Operating expenses:
Sales and marketing	2,735	2,380	8,151	6,754
Research and development	2,216	1,713	6,586	4,438
General and administrative	2,318	1,556	8,271	5,090
Total operating expenses	7,269	5,649	23,008	16,282
Loss from operations	(6,866)	(5,181)	(20,904)	(14,909)
Other income (expense), net:
Gain (loss) on warrant liability	(1,620)	0	3,030	0
Interest and other, net	8	(4)	(20)	(36)
Total other income (expense), net	(1,612)	(4)	3,010	(36)
Net loss	(8,478)	(5,185)	(17,894)	(14,945)
Less: Preferred deemed dividend	(3,016)	0	(10,345)	0
Net loss applicable to common shareholders	(11,494)	(5,185)	(28,239)	(14,945)
Foreign currency translation adjustments	(17)	0	(6)	0
Comprehensive loss	$ (11,511)	$ (5,185)	$ (28,245)	$ (14,945)
Basic net loss per share applicable to common shareholders (in dollars per share)	$ (0.60)	$ (0.35)	$ (1.67)	$ (1.03)
Weighted average number of shares of common stock outstanding, basic (in shares)	19,005	14,606	16,888	14,578
Diluted net loss per share applicable to common shareholders (in dollars per share)	$ (0.60)	$ (0.35)	$ (1.78)	$ (1.03)
Weighted average number of shares of common stock outstanding, diluted (in shares)	19,005	14,606	17,595	14,578

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Operating activities:
Net loss	$ (17,894)	$ (14,945)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	1,381	653
Amortization of deferred rent	(27)	(28)
Stock-based compensation expense	2,552	1,259
Gain on change in fair value of warrant liability	(3,030)	0
Changes in operating assets and liabilities:
Accounts receivable	(131)	(636)
Inventories	(1,026)	(379)
Note receivable	(75)	0
Prepaid expense and other assets	(94)	(338)
Deferred costs of revenue	4,498	(776)
Accounts payable	(1,335)	1,365
Accrued liabilities	1,279	(188)
Deferred revenues	(6,653)	931
Net cash used in operating activities	(20,555)	(13,082)
Investing activities:
Acquisition of property and equipment	(728)	(962)
Net cash used in investing activities	(728)	(962)
Financing activities:
Principal payments on note payable	(58)	(40)
Fees paid related to 2015 issuance of convertible preferred stock	(173)	0
Proceeds from issuance of common stock	14,694	0
Proceeds from exercise of stock options	74	80
Proceeds from exercise of warrants	0	52
Net cash provided by financing activities	14,537	92
Effect of exchange rate changes on cash	(6)	0
Net decrease in cash	(6,752)	(13,952)
Cash at beginning of period	19,552	25,190
Cash at end of period	$ 12,800	$ 11,238

Organization

Organization	9 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	1. Organization Description of Business On January 15, 2014, a wholly-owned subsidiary of Ekso Bionics Holdings, Inc. named Ekso Acquisition Corp. merged with and into Ekso Bionics, Inc. (the “Merger”). Ekso Bionics, Inc. was the surviving corporation and became a wholly-owned subsidiary of Ekso Bionics Holdings, Inc. As a result of this transaction, Ekso Bionics Holdings, Inc. discontinued its pre-merger operations, acquired the business of Ekso Bionics, Inc. and continues the operations of Ekso Bionics, Inc. as a publicly traded company. Ekso Bionics, Inc. was incorporated in January 2005 in the State of Delaware. As used in these notes to the consolidated financial statements, the term “the Company” refers to Ekso Bionics Holdings, Inc., formerly known as PN Med Group, Inc., and its wholly-owned subsidiaries, including Ekso Bionics, Inc. after giving effect to the Merger; the term “Holdings” refers to the business of Ekso Bionics Holdings, Inc. prior to the Merger, and the term “Ekso Bionics” refers to Ekso Bionics, Inc. prior to the Merger. All common stock share and per share amounts have been adjusted to reflect the one-for-seven reverse stock split completed on May 4, 2016. See Note 11, Capitalization and Equity Structure – Reverse Stock Split The Company designs, develops, and sells exoskeletons that augment human strength, endurance, and mobility. The Company’s exoskeletons have applications in health care, industrial, military, and consumer markets. Liquidity Largely as a result of significant research and development activities related to the development of the Company’s advanced technology and commercialization of this technology into its medical device business, the Company has incurred significant operating losses and negative cash flows from operations since inception. The Company has also recognized significant non-cash losses associated with the revaluation of certain securities, which have also contributed significantly to its accumulated deficit. As of September 30, 2016, the Company had an accumulated deficit of $ 109,284 Cash on hand at September 30, 2016 was $ 12,800 19,552 20,555 13,082 expand commercialization efforts for Based upon the Company’s current cash resources, which include cash received from the exercise of warrants since September 30, 2016, the recent rate of using cash for operations and investment, and assuming modest increases in current revenue offset by incremental increases in expenses related to increased sales and marketing and research and development, and a potential increase in rental activity from its medical device business, the Company believes it has sufficient resources to meet its financial obligations into the second quarter of 2017 . The Company will require significant additional financing. The Company intends to pursue opportunities to obtain additional financing in the future through public or private equity and/or debt financings, corporate collaborations, or warrant solicitations. The Company’s actual capital requirements may vary significantly and will depend on many factors. For example, the Company plans to continue to increase its investments (i) in its clinical, sales and marketing initiatives to accelerate adoption of the Ekso robotic exoskeleton in the rehabilitation market, (ii) in its research, development and commercialization activities with respect to an Ekso robotic exoskeleton for home use, and/or (iii) in the development and commercialization of able-bodied exoskeletons for industrial use. Consequently, the Company will require significant additional financing in the future, which the Company intends to raise through corporate collaborations, public or private equity offerings, debt financings, or warrant solicitations. Sales of additional equity securities by us could result in the dilution of the interests of existing stockholders. There can be no assurance that financing will be available when required in sufficient amounts, on acceptable terms or at all. In the event that the necessary additional financing is not obtained, the Company may be required to reduce its discretionary overhead costs substantially, including research and development, general and administrative, and sales and marketing expenses or otherwise curtail operations.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies and Estimates	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies and Estimates	2. Basis of Presentation and Summary of Significant Accounting Policies and Estimates These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for the presentation of interim financial information. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed, or omitted, pursuant to such rules and regulations. The condensed consolidated balance sheet at December 31, 2015, has been derived from the audited consolidated financial statements at that date but does not include all disclosures required for the annual financial statements and should be read in conjunction with our audited consolidated financial statements and notes thereto included as part of our Annual Report on Form 10-K for the year ended December 31, 2015. Unless otherwise indicated, all dollar and share amounts (excluding per share amounts) included in these notes to the financial statements are in thousands. In management’s opinion, the condensed consolidated financial statements reflect all adjustments (including reclassifications and normal recurring adjustments) necessary for a fair statement of its financial position at September 30, 2016, and results of operations and cash flows for all periods presented. The interim results presented are not necessarily indicative of results that can be expected for a full year. The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Certain reclassifications have been made to conform to the current period’s presentation. The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to: revenue recognition, deferred revenue and the deferral of the associated costs, future warranty costs, maintenance and planned improvement costs associated with medical device units sold prior to 2016, useful lives assigned to long-lived assets, realizability of deferred tax assets, the valuation of options and warrants, and contingencies. Actual results could differ from those estimates. Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash and accounts receivable. We maintain our cash accounts in excess of federally insured limits. However, we believe we are not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. We extend credit to customers in the normal course of business and perform ongoing credit evaluations of our customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. We do not require collateral from our customers to secure accounts receivable. Accounts receivable are derived from the sale of products shipped and services performed for customers located in the U.S. and throughout the world. Invoices are aged based on contractual terms with the customer. We review accounts receivable for collectability and provide an allowance for credit losses, as needed. We have not experienced any material losses related to accounts receivable as of September 30, 2016 and December 31, 2015. Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. We do not enter into any foreign currency hedging agreements and are susceptible to gains and losses from foreign currency fluctuations. To date, we have not experienced significant gains or losses upon settling foreign currency denominated accounts receivable. As of September 30, 2016, we had one customer with an accounts receivable balance totaling 10 13 10 In the three months ended September 30, 2016, we had one customer with billed revenue of 10 15 48 10 33 The Company builds medical device robotic exoskeletons for sale and capitalizes into inventory materials, direct and indirect labor, and overhead in connection with the manufacture and assembly of these units. When the Company brought its first version medical device to market in 2012, the Company could not be certain as to the costs it would incur to support, maintain, service, and upgrade these early stage devices. Primarily for this reason, prior to January 1, 2016, the sale of a device, associated software, initial training, and extended support and maintenance were deemed as a single unit of accounting due to the uncertainty of the Company’s follow-up maintenance and upgrade expenses, which were forecast to extend over three years. Accordingly, the revenue from the sales of the device and associated cost of revenue were deferred at the time of shipment. Upon completion of training, such amounts were recognized as revenue and cost of revenue over a three year period on a straight line basis, while all service expenses, whether or not covered by the Company’s original warranty, extended warranty contracts, or neither, were recognized as incurred. Effective January 1, 2016, the Company determined it had established (i) separate individual pricing for training, extended warranty coverage, and out-of-contract service or repairs, (ii) sufficient historical evidence of customer buying patterns for extended warranty and maintenance coverage, and (iii) a basis for estimating and recording warranty and service costs to allow the Company to separate multiple element arrangements distinct As a result, the on such multiple element arrangements 6,517 4,159 2,358 212 911 In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-09, Compensation – Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date Revenue from Contracts with Customers (Topic 606) Identifying Performance Obligations and Licensing Revenue from Contracts with Customers (Topic 606) Narrow-Scope Improvements and Practical Expedients In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	9 Months Ended
	Sep. 30, 2016
Disclosure Text Block [Abstract]
Accumulated Other Comprehensive Loss	3. Accumulated Other Comprehensive Loss Foreign Currency Translation Balance at December 31, 2015 $ (1) Other comprehensive loss before reclassification (6) Amounts reclassified from accumulated other - Net current period other comprehensive loss (6) Balance at September 30, 2016 $ (7)

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. Fair Value Measurements Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Three levels of inputs, of which the first two are considered observable and the last unobservable, may be used to measure fair value which are the following: • Level 1 • Level 2 • Level 3 The Company’s fair value hierarchies for its financial assets and liabilities which require fair value measurement are as follows: Quoted Prices in Active Markets For Significant Other Observable Inputs Significant Unobservable Inputs Total (Level 1) (Level 2) (Level 3) September 30, 2016 Liabilities Warrant liability $ (6,165) $ - $ - $ (6,165) Contingent consideration liability $ (768) $ - $ - $ (768) December 31, 2015 Liabilities Warrant liability $ (9,195) $ - $ - $ (9,195) Contingent consideration liability $ (768) $ - $ - $ (768) Warrant Liability Contingent Consideration Liability Balance at December 31, 2015 $ (9,195) $ (768) Gain on decrease in fair value of warrants issued with 2015 financing 3,030 - Balance at September 30, 2016 $ (6,165) $ (768) Refer to Note 11. Capitalization and Equity Structure – Warrants

Inventories, net

Inventories, net	9 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Inventories, net	5. Inventories, net September 30, December 31, 2016 2015 Raw materials $ 1,380 $ 783 Work in process 432 336 Finished goods 151 19 1,963 1,138 Less: inventory reserve (48) (82) Inventories, net $ 1,915 $ 1,056

Deferred Revenues

Deferred Revenues	9 Months Ended
	Sep. 30, 2016
Deferred Revenue Disclosure [Abstract]
Deferred Revenues	6. Deferred Revenues In connection with our medical device sales and engineering services, the Company often receives cash payments before the earnings process is complete. In these instances, the Company records the payments as customer deposits until a device is shipped to the customer, or as customer advances in the case of engineering services until the earnings process is achieved. In both cases, the cash received is recorded as a component of deferred revenue. As described in Note 2. Basis of Presentation and Summary of Significant Accounting Policies and Estimates – Medical Device Revenue and Cost of Revenue Recognition, one four 6,517 4,159 September 30, 2016 December 31, 2015 Customer deposits and advances $ 60 $ 48 Deferred medical device revenues 301 7,388 Deferred rental income 74 71 Deferred extended maintenance and support 1,485 1,066 Total deferred revenues 1,920 8,573 Less current portion (1,098) (3,960) Deferred revenues, non-current $ 822 $ 4,613 Deferred medical device unit costs $ 92 $ 4,590 Less current portion (92) (2,088) Deferred cost of revenue, non-current $ - $ 2,502

Intangible Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	7. Intangible Assets On December 1, 2015, the Company acquired substantially all of the assets of Equipois, LLC, a New Hampshire limited liability company, for an initial payment of $ 1,071 768 1,610 Cost Accumulated Amortization Net Developed technology $ 1,160 $ (323) $ 837 Customer relationships 70 (19) 51 Customer trade name 380 (106) 274 $ 1,610 $ (448) $ 1,162 Estimated future amortization for the remainder of 2016 is $ 135 537 490

Accrued Liabilities

Accrued Liabilities	9 Months Ended
	Sep. 30, 2016
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Liabilities	8. Accrued Liabilities September 30, December 31, 2016 2015 Salaries, benefits and related expenses $ 1,988 $ 1,464 Maintenance 579 - Warranty expense 186 - Professional fees 137 257 Other 92 164 Total $ 2,982 $ 1,885

Maintenance and Warranty

Maintenance and Warranty	9 Months Ended
	Sep. 30, 2016
Maintenance And Warranty [Abstract]
Maintenance and Warranty	9. Maintenance and Warranty Sales of devices generally include an initial warranty for parts and services for one year in the U.S. and two years in Europe, the Middle East, and Africa. During the nine months ended September 30, 2016, the Company determined it had sufficient historical experience of warranty costs to estimate future warranty costs for devices sold. As a result, and beginning during the nine months ended September 30, 2016, a liability for the estimated cost of product warranty is established at the time revenue is recognized based on the historical experience of known product failure rates and expected material and labor costs to provide warranty services. From time to time, specific additional warranty accruals may be made if unforeseen technical problems arise. Alternatively, if estimates are determined to be greater than the actual amounts necessary, a portion of the liability may be reversed in future periods. Warranty costs are reflected in the condensed consolidated statements of operations and comprehensive loss as a component of costs of revenue. In addition, in the nine months ended September 30, 2016, the Company recorded in its condensed consolidated statements of operations and comprehensive loss a one-time charge of $ 911 2016 Maintenance Warranty Total Balance at December 31, 2015 $ - $ - $ - Additions for estimated future expense 911 356 1,267 Incurred costs (332) (161) (493) Balance at September 30, 2016 $ 579 $ 195 $ 774 Current portion 579 186 765 Long-term portion - 9 9 Total $ 579 $ 195 $ 774 The long-term portion of warranty accrual is included as a component of other non-current liabilities in the condensed consolidated balance sheets.

Lease and Note Obligations

Lease and Note Obligations	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Lease and Note Obligations	10. Lease and Note Obligations In November 2011, the Company entered into an operating lease agreement for its headquarters and manufacturing facility in Richmond, California. The lease term commenced in March 2012 and expires in May 2017, with one option to renew for an additional five years. In November 2016, the Company signed the five-year lease extension option for its Richmond headquarters. The option lease term will commence in June 2017 and expire in May 2022, which is included in the table below. The Company also leases nominal office space in Germany. In 2012, the Company entered into a note agreement in connection with the lease for its Richmond, California facility. The note, for an aggregate principal of $ 200 7 4 May 31, 2017 166 4.7 3 July 1, 2020 Period Operating Lease Note Payable Capital Lease Total Minimum Payments 2016 - remainder $ 116 $ 12 $ 11 $ 23 2017 461 20 40 60 2018 483 - 37 37 2019 494 - 37 37 2020 504 - 22 22 Thereafter 610 - - - Total minimum payments $ 2,668 32 147 179 Less interest (1) (12) (13) Present value minimum payments 31 135 166 Less current portion (31) (36) (67) Long-term portion $ - $ 99 $ 99 Rent expense under the Company’s operating leases was $ 101 86 299 258

Capitalization and Equity Struc

Capitalization and Equity Structure	9 Months Ended
	Sep. 30, 2016
Stockholders' Equity Note [Abstract]
Capitalization and Equity Structure	11. Capitalization and Equity Structure Reverse Stock Split: After the close of the stock market on May 4, 2016, the Company effected a 1-for-7 reverse split Summary: The Company’s authorized capital stock at September 30, 2016 consisted of 71,429 10,000 21,393 2016 Common Stock Offering: On August 12, 2016, the Company issued 3,750 4.00 13,696 267 998 As discussed below, the Series A Convertible Preferred Stock issued in December 2015 (the “Preferred Shares”) and the common stock warrants issued in December 2015 (the “2015 Warrants”) included price-based anti-dilution provisions providing for the adjustment of the conversion price and the exercise price, as applicable, in the event the Company sells common stock or common stock equivalents (subject to exceptions for certain exempt issuances) at a price lower than the then-conversion price of the Preferred Shares or the then-exercise price of the 2015 Warrants. Because the sale price to the underwriters of the common stock in the August 2016 common stock offering was less than the then-conversion price of the Preferred Shares and the then-exercise price of the 2015 Warrants, there was an anti-dilution adjustment to the number of shares of common stock issuable upon conversion of the Preferred Shares and the exercise price of the 2015 Warrants was reduced, as discussed in more detail below. Convertible Preferred Stock: In December 2015, the Company issued 15 Preferred Shares and 2015 Warrants to purchase 2,122 15,000 0.141 7.07 3.74 0.267 3 921 At December 31, 2015, 13 1 60 3 921 10 1,389 7.07 3 921 3.74 3,016 10,345 Warrants: Source Exercise Price Term (Years) At December 31, 2015 At September 30, 2016 December 2015 warrants $ 3.74 5 2,122 2,122 2014 PPO and Merger Placement agent warrants $ 7.00 5 426 426 Bridge warrants $ 7.00 3 371 371 PPO warrants $ 14.00 5 1,078 1,078 Pre 2014 warrants $ 9.66 various 88 88 4,085 4,085 In connection with the December 2015 issuance of Preferred Shares discussed above, the Company issued 2015 Warrants to purchase up to an aggregate of 2,122 5 8.75 3.74 The Company estimates the fair value of the warrant liability by using a Black Scholes Option Pricing Model. The warrant liability is measured at fair value using certain estimated inputs, which are classified within Level 3 of the valuation hierarchy. The following assumptions were used in the Black Scholes Option Pricing Model to measure the fair value of the warrants as of September 30, 2016: Current share price $ 4.70 Conversion price $ 3.74 Risk-free interest rate 1.04 % Term (years) 4.23 Volatility of stock 75 % The warrants were valued at $ 9,195 3,030 1,620 Subsequent events: During the fourth quarter through October 30, 2016, the Company received proceeds of $ 1,825 488 488 3.74

Stock-based Compensation

Stock-based Compensation	9 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation	12. Stock-based Compensation See Note 11, Capitalization and Equity Structure – Reverse Stock Split The Company’s Amended and Restated 2014 Equity Incentive Plan (the “2014 Plan”) allows for the issuance of an aggregate of 3,714 965 Weighted- Average Weighted- Remaining Average Contractual Aggregate Stock Awards Exercise Price Life (Years) Intrinsic Value Balance as of December 31, 2015 1,963 $ 7.09 Options granted 776 $ 5.44 Options exercised (30) $ 2.40 Options forfeited (207) $ 8.11 Options cancelled (28) $ 9.58 Balance as of September 30, 2016 2,474 $ 6.51 7.66 $ 1,322 Vested and expected to vest at September 30, 2016 2,294 7.53 $ 1,279 Exercisable as of September 30, 2016 1,180 6.03 $ 1,089 As of September 30, 2016, total unrecognized compensation cost related to unvested stock options was $ 5,360 2.8 Three months ended September 30, Nine months ended September 30, 2016 2015 2016 2015 Dividend yield — — — — Risk-free interest rate 1.25% – 1.26% 1.68% 1.24% - 1.78% 1.41% - 2.50% Expected term (in years) 6 6 5-10 6-10 Volatility 80% 75% 77-80% 73% - 75% Three months ended September 30, Nine months ended September 30, 2016 2015 2016 2015 Sales and marketing $ 103 $ 147 $ 541 $ 440 Research and development 127 133 499 295 General and administrative 221 187 1,512 524 $ 451 $ 467 $ 2,552 $ 1,259 In connection with the resignation of the Company’s then Chief Executive Officer in February 2016, the Company accelerated the vesting of options that would have vested in the subsequent twelve months and extended the exercise period of the resulting options from three months to six years. In addition, the Company extended the exercise period for an employee that was terminated in March 2016 from three months to one year. These modifications resulted in incremental stock-based compensation expense of $ 59 774

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Income Taxes	13. Income Taxes There were no material changes to the unrecognized tax benefits in the nine months ended September 30, 2016, and the Company does not expect significant changes to unrecognized tax benefits through the end of the fiscal year. Because of the Company’s history of tax losses, all years remain open to tax examination.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	14. Commitments and Contingencies Contingencies In the normal course of business, the Company is subject to various legal matters. In the opinion of management, the resolution of such matters will not have a material adverse effect on the Company’s condensed consolidated financial statements. Material Contracts The Company enters into various license, research collaboration and development agreements which provide for payments to the Company for government grants, fees, cost reimbursements typically with a markup, technology transfer and license fees, and royalty payments on sales. The Company has two license agreements to maintain exclusive rights to patents. The Company is also required to pay 1 21 1 50 In connection with acquisition of Equipois, the Company assumed the rights and obligations of Equipois under a license agreement with Garrett Brown, the developer of certain intellectual property related to mechanical balance and support arm technologies, which grants the Company an exclusive license with respect to the technology and patent rights for certain fields of use. Pursuant to the terms of the license agreement, the Company will be required to pay Mr. Brown a single-digit royalty on net receipts, subject to a $ 50 The Company entered into a supply agreement with Equipois to purchase mechanical arm products on a quarterly basis commencing on December 1, 2015 through December 31, 2016, with a minimum annual price of $ 157 U.S. Food and Drug Administration Clearance On April 4, 2016, the Company received clearance from the U.S. Food and Drug Administration (“FDA”) to market its Ekso GT robotic exoskeleton for use in the treatment of individuals with hemiplegia due to stroke, individuals with spinal cord injuries at levels T4 to L5, and individuals with spinal cord injuries at levels of T3 to C7 (ASIA D), in accordance with the device’s labeling. On July 19, 2016, the Company received clearance from the FDA to expand/clarify the indications and labeling to expressly include individuals with hemiplegia due to stroke who have upper extremity function of at least 4/5 in only one arm. The Company’s prior cleared indications for use statement required that individuals with hemiplegia due to stroke have upper extremity function of at least 4/5 in both arms. The Company believes that prior to April 4, 2016, the Company’s Ekso GT robotic exoskeleton had been appropriately marketed in the United States as a Class I 510(k) exempt Powered Exercise Equipment device since February 2012. On June 26, 2014, the FDA announced the creation of a new product classification for Powered Exoskeleton devices. On October 21, 2014, the FDA published the summary for the new Powered Exoskeleton classification and designated it as being Class II, which requires the clearance of a 510(k) notice. On October 21, 2014, concurrent with the FDA’s publication of the reclassification of Powered Exoskeleton devices, the FDA issued the Company an “Untitled Letter” which informed the Company in writing of the agency’s belief that this new product classification applied to the Ekso GT device. On December 24, 2014, the Company filed a 510(k) notice for the Ekso robotic exoskeleton which was accepted by the FDA for substantive review on July 29, 2015. As discussed above, the Company received FDA clearance to market the Ekso GT in accordance with the device’s labeling on April 4, 2016. From September 2, 2015 to September 11, 2015, the Division of Bioresearch Monitoring Center for Devices and Radiological Health of the FDA conducted an inspection of the Company’s facility in Richmond, California. At the conclusion of the inspection, the FDA issued a Form FDA 483 with four observations. These observations were inspectional and did not represent a final FDA determination of non-compliance. The observations pertained to informed consent requirements, reporting of adverse results and records maintenance. On October 2, 2015, the Company responded to the FDA describing the corrective and preventive actions that the Company had implemented and continued to implement to address the FDA’s concerns. On March 30, 2016, the FDA accepted the Company’s corrective actions for the Form 483 observations that were generated during the FDA’s inspection.

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Net Loss Per Share	15. Net Loss Per Share Three months ended Nine months ended 2016 2015 2016 2015 Numerator: Net loss applicable to common stockholders Basic $ (11,494) $ (5,185) $ (28,239) $ (14,945) Adjustment for revaluation of warrant liability - - (3,030) - Diluted $ (11,494) $ (5,185) $ (31,269) $ (14,945) Denominator: Weighted-average number of shares, basic 19,005 14,606 16,888 14,578 Effect of dilutive warrants - - 707 - Weighted-average numbers of shares, diluted 19,005 14,606 17,595 14,578 Net loss per share, basic $ (0.60) $ (0.35) $ (1.67) $ (1.03) Net loss per share, diluted $ (0.60) $ (0.35) $ (1.78) $ (1.03) Recognition of previously deferred revenue and cost of goods in the nine months ended September 30, 2016 reduced net loss applicable to common stockholders by $ 2,358 0.14 Note 2. Basis of Presentation and Summary of Significant Accounting Policies and Estimates – Medical Device Revenue and Cost of Revenue Recognition Three months ended Nine months ended 2016 2015 2016 2015 Options to purchase common stock 2,474 1,832 2,474 1,832 Warrants for common stock 4,085 1,963 1,963 1,963 Total common stock equivalents 6,559 3,795 4,437 3,795

Segment Disclosures

Segment Disclosures	9 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Segment Disclosures	16. Segment Disclosures During the third quarter of 2016, the Company determined industrial sales to be a reportable segment as a result of progress in commercialization and sales of its industrial devices. We have recast certain prior period amounts to conform to the way we internally manage and monitor segment performance. The Company has three reportable segments, Medical Devices, Industrial Sales, and Engineering Services. The Medical Devices segment designs and engineers technology for, and commercializes, manufactures, and sells exoskeletons for applications in the medical markets. The Industrial Sales segment designs, engineers, commercializes, and sells exoskeleton devices to allow able-bodied users to perform heavy duty work for extended periods. Engineering Services generates revenue principally from collaborative research and development service arrangements, technology license agreements, and government grants where the Company uses its robotics domain knowledge in bionic exoskeletons to bid on and procure contracts and grants from entities such as the National Science Foundation and the Defense Advanced Research Projects Agency. The Company evaluates performance and allocates resources based on segment gross profit margin. The reportable segments are each managed separately because they serve distinct markets, and one segment provides a service and the others manufacture and distribute unique products. The Company does not consider net assets as a segment measure and, accordingly, assets are not allocated. Medical Industrial Engineering Devices Sales Services Total Three months ended September 30, 2016 Revenue $ 1,089 $ 406 $ 101 $ 1,596 Cost of revenue 833 290 70 1,193 Gross profit $ 256 $ 116 $ 31 $ 403 Three months ended September 30, 2015 Revenue $ 1,095 $ - $ 1,820 $ 2,915 Cost of revenue 1,095 - 1,352 2,447 Gross profit $ - $ - $ 468 $ 468 Nine months ended September 30, 2016 Revenue $ 10,321 $ 682 $ 631 $ 11,634 Cost of revenue 8,543 535 452 9,530 Gross profit $ 1,778 $ 147 $ 179 $ 2,104 Nine months ended September 30, 2015 Revenue $ 3,128 $ - $ 3,590 $ 6,718 Cost of revenue 2,863 - 2,482 5,345 Gross profit $ 265 $ - $ 1,108 $ 1,373 Three months ended September 30, Nine months ended September 30, 2016 2015 2016 2015 North America $ 1,243 $ 2,379 $ 6,940 $ 5,272 All Other 353 536 4,694 1,446 $ 1,596 $ 2,915 $ 11,634 $ 6,718

Basis of Presentation and Sum22

Basis of Presentation and Summary of Significant Accounting Policies and Estimates (Policies)	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for the presentation of interim financial information. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed, or omitted, pursuant to such rules and regulations. The condensed consolidated balance sheet at December 31, 2015, has been derived from the audited consolidated financial statements at that date but does not include all disclosures required for the annual financial statements and should be read in conjunction with our audited consolidated financial statements and notes thereto included as part of our Annual Report on Form 10-K for the year ended December 31, 2015. Unless otherwise indicated, all dollar and share amounts (excluding per share amounts) included in these notes to the financial statements are in thousands. In management’s opinion, the condensed consolidated financial statements reflect all adjustments (including reclassifications and normal recurring adjustments) necessary for a fair statement of its financial position at September 30, 2016, and results of operations and cash flows for all periods presented. The interim results presented are not necessarily indicative of results that can be expected for a full year. The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Certain reclassifications have been made to conform to the current period’s presentation.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to: revenue recognition, deferred revenue and the deferral of the associated costs, future warranty costs, maintenance and planned improvement costs associated with medical device units sold prior to 2016, useful lives assigned to long-lived assets, realizability of deferred tax assets, the valuation of options and warrants, and contingencies. Actual results could differ from those estimates.
Concentration of Credit Risk and Other Risks and Uncertainties	Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash and accounts receivable. We maintain our cash accounts in excess of federally insured limits. However, we believe we are not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. We extend credit to customers in the normal course of business and perform ongoing credit evaluations of our customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. We do not require collateral from our customers to secure accounts receivable. Accounts receivable are derived from the sale of products shipped and services performed for customers located in the U.S. and throughout the world. Invoices are aged based on contractual terms with the customer. We review accounts receivable for collectability and provide an allowance for credit losses, as needed. We have not experienced any material losses related to accounts receivable as of September 30, 2016 and December 31, 2015. Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. We do not enter into any foreign currency hedging agreements and are susceptible to gains and losses from foreign currency fluctuations. To date, we have not experienced significant gains or losses upon settling foreign currency denominated accounts receivable. As of September 30, 2016, we had one customer with an accounts receivable balance totaling 10 13 10 In the three months ended September 30, 2016, we had one customer with billed revenue of 10 15 48 10 33
Medical Device Revenue and Cost of Revenue Recognition	Medical Device Revenue and Cost of Revenue Recognition The Company builds medical device robotic exoskeletons for sale and capitalizes into inventory materials, direct and indirect labor, and overhead in connection with the manufacture and assembly of these units. When the Company brought its first version medical device to market in 2012, the Company could not be certain as to the costs it would incur to support, maintain, service, and upgrade these early stage devices. Primarily for this reason, prior to January 1, 2016, the sale of a device, associated software, initial training, and extended support and maintenance were deemed as a single unit of accounting due to the uncertainty of the Company’s follow-up maintenance and upgrade expenses, which were forecast to extend over three years. Accordingly, the revenue from the sales of the device and associated cost of revenue were deferred at the time of shipment. Upon completion of training, such amounts were recognized as revenue and cost of revenue over a three year period on a straight line basis, while all service expenses, whether or not covered by the Company’s original warranty, extended warranty contracts, or neither, were recognized as incurred. Effective January 1, 2016, the Company determined it had established (i) separate individual pricing for training, extended warranty coverage, and out-of-contract service or repairs, (ii) sufficient historical evidence of customer buying patterns for extended warranty and maintenance coverage, and (iii) a basis for estimating and recording warranty and service costs to allow the Company to separate multiple element arrangements distinct As a result, the on such multiple element arrangements 6,517 4,159 2,358 212 911
Recent Accounting Pronouncements	Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-09, Compensation – Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date Revenue from Contracts with Customers (Topic 606) Identifying Performance Obligations and Licensing Revenue from Contracts with Customers (Topic 606) Narrow-Scope Improvements and Practical Expedients In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments

Accumulated Other Comprehensi23

Accumulated Other Comprehensive Loss (Tables)	9 Months Ended
	Sep. 30, 2016
Disclosure Text Block [Abstract]
Schedule of Accumulated Other Comprehensive Loss	The change in accumulated other comprehensive loss presented on the condensed consolidated balance sheets and the impact of significant amounts reclassified from accumulated other comprehensive loss on information presented in the condensed consolidated statements of operations and comprehensive loss for the nine month period ending September 30, 2016, are reflected in the table below net of tax: Foreign Currency Translation Balance at December 31, 2015 $ (1) Other comprehensive loss before reclassification (6) Amounts reclassified from accumulated other - Net current period other comprehensive loss (6) Balance at September 30, 2016 $ (7)

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The Company’s fair value hierarchies for its financial assets and liabilities which require fair value measurement are as follows: Quoted Prices in Active Markets For Significant Other Observable Inputs Significant Unobservable Inputs Total (Level 1) (Level 2) (Level 3) September 30, 2016 Liabilities Warrant liability $ (6,165) $ - $ - $ (6,165) Contingent consideration liability $ (768) $ - $ - $ (768) December 31, 2015 Liabilities Warrant liability $ (9,195) $ - $ - $ (9,195) Contingent consideration liability $ (768) $ - $ - $ (768)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities for the nine month period ended September 30, 2016, which were measured at fair value on a recurring basis: Warrant Liability Contingent Consideration Liability Balance at December 31, 2015 $ (9,195) $ (768) Gain on decrease in fair value of warrants issued with 2015 financing 3,030 - Balance at September 30, 2016 $ (6,165) $ (768)

Inventories, net (Tables)

Inventories, net (Tables)	9 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Schedule of Inventory, Net	Inventories consist of the following: September 30, December 31, 2016 2015 Raw materials $ 1,380 $ 783 Work in process 432 336 Finished goods 151 19 1,963 1,138 Less: inventory reserve (48) (82) Inventories, net $ 1,915 $ 1,056

Deferred Revenues (Tables)

Deferred Revenues (Tables)	9 Months Ended
	Sep. 30, 2016
Deferred Revenue Disclosure [Abstract]
Schedule of Deferred Cost of Revenues	Deferred revenues and deferred cost of revenues consist of the following: September 30, 2016 December 31, 2015 Customer deposits and advances $ 60 $ 48 Deferred medical device revenues 301 7,388 Deferred rental income 74 71 Deferred extended maintenance and support 1,485 1,066 Total deferred revenues 1,920 8,573 Less current portion (1,098) (3,960) Deferred revenues, non-current $ 822 $ 4,613 Deferred medical device unit costs $ 92 $ 4,590 Less current portion (92) (2,088) Deferred cost of revenue, non-current $ - $ 2,502

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of Purchased Intangible Assets	The following table reflects the amortization of the purchased intangible assets as of September 30, 2016: Cost Accumulated Amortization Net Developed technology $ 1,160 $ (323) $ 837 Customer relationships 70 (19) 51 Customer trade name 380 (106) 274 $ 1,610 $ (448) $ 1,162

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2016
Accrued Liabilities and Other Liabilities [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consist of the following: September 30, December 31, 2016 2015 Salaries, benefits and related expenses $ 1,988 $ 1,464 Maintenance 579 - Warranty expense 186 - Professional fees 137 257 Other 92 164 Total $ 2,982 $ 1,885

Maintenance and Warranty (Table

Maintenance and Warranty (Tables)	9 Months Ended
	Sep. 30, 2016
Maintenance And Warranty [Abstract]
Reconciliation of Changes in Maintenance and Warranty Liabilities	2016 Maintenance Warranty Total Balance at December 31, 2015 $ - $ - $ - Additions for estimated future expense 911 356 1,267 Incurred costs (332) (161) (493) Balance at September 30, 2016 $ 579 $ 195 $ 774 Current portion 579 186 765 Long-term portion - 9 9 Total $ 579 $ 195 $ 774

Lease and Note Obligations (Tab

Lease and Note Obligations (Tables)	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Schedule of Estimates Future Minimum Payments	The Company estimates future minimum payments as of September 30, 2016 to be the following: Period Operating Lease Note Payable Capital Lease Total Minimum Payments 2016 - remainder $ 116 $ 12 $ 11 $ 23 2017 461 20 40 60 2018 483 - 37 37 2019 494 - 37 37 2020 504 - 22 22 Thereafter 610 - - - Total minimum payments $ 2,668 32 147 179 Less interest (1) (12) (13) Present value minimum payments 31 135 166 Less current portion (31) (36) (67) Long-term portion $ - $ 99 $ 99

Capitalization and Equity Str31

Capitalization and Equity Structure (Tables)	9 Months Ended
	Sep. 30, 2016
Schedule of Capitalization, Equity [Line Items]
Schedule of Warrant share activity	Warrant share activity for the nine month period ended September 30, 2016 is as follows: Source Exercise Price Term (Years) At December 31, 2015 At September 30, 2016 December 2015 warrants $ 3.74 5 2,122 2,122 2014 PPO and Merger Placement agent warrants $ 7.00 5 426 426 Bridge warrants $ 7.00 3 371 371 PPO warrants $ 14.00 5 1,078 1,078 Pre 2014 warrants $ 9.66 various 88 88 4,085 4,085
2016 Warrants [Member]
Schedule of Capitalization, Equity [Line Items]
Schedule of assumption used in valuation	The following assumptions were used in the Black Scholes Option Pricing Model to measure the fair value of the warrants as of September 30, 2016: Current share price $ 4.70 Conversion price $ 3.74 Risk-free interest rate 1.04 % Term (years) 4.23 Volatility of stock 75 %

Stock-based Compensation (Table

Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Stock Option Outstanding and Activity	The following table summarizes information about the Company’s stock options outstanding at September 30, 2016, and activity during the nine month period then ended: Weighted- Average Weighted- Remaining Average Contractual Aggregate Stock Awards Exercise Price Life (Years) Intrinsic Value Balance as of December 31, 2015 1,963 $ 7.09 Options granted 776 $ 5.44 Options exercised (30) $ 2.40 Options forfeited (207) $ 8.11 Options cancelled (28) $ 9.58 Balance as of September 30, 2016 2,474 $ 6.51 7.66 $ 1,322 Vested and expected to vest at September 30, 2016 2,294 7.53 $ 1,279 Exercisable as of September 30, 2016 1,180 6.03 $ 1,089
Schedule of Fair Value Calculation Assumptions	The per-share fair value of each stock option was determined on the date of grant using the Black-Scholes option pricing model using the following assumptions: Three months ended September 30, Nine months ended September 30, 2016 2015 2016 2015 Dividend yield — — — — Risk-free interest rate 1.25% – 1.26% 1.68% 1.24% - 1.78% 1.41% - 2.50% Expected term (in years) 6 6 5-10 6-10 Volatility 80% 75% 77-80% 73% - 75%
Schedule of Stock-Based Compensation Expense Related to Options Granted to Employees and Non-employees	Total stock-based compensation expense related to options granted to employees and non-employees was included in the condensed consolidated statements of operations and comprehensive loss as follows: Three months ended September 30, Nine months ended September 30, 2016 2015 2016 2015 Sales and marketing $ 103 $ 147 $ 541 $ 440 Research and development 127 133 499 295 General and administrative 221 187 1,512 524 $ 451 $ 467 $ 2,552 $ 1,259

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss Per Share	Three months ended Nine months ended 2016 2015 2016 2015 Numerator: Net loss applicable to common stockholders Basic $ (11,494) $ (5,185) $ (28,239) $ (14,945) Adjustment for revaluation of warrant liability - - (3,030) - Diluted $ (11,494) $ (5,185) $ (31,269) $ (14,945) Denominator: Weighted-average number of shares, basic 19,005 14,606 16,888 14,578 Effect of dilutive warrants - - 707 - Weighted-average numbers of shares, diluted 19,005 14,606 17,595 14,578 Net loss per share, basic $ (0.60) $ (0.35) $ (1.67) $ (1.03) Net loss per share, diluted $ (0.60) $ (0.35) $ (1.78) $ (1.03)
Schedule of Antidilutive Securities	Three months ended Nine months ended 2016 2015 2016 2015 Options to purchase common stock 2,474 1,832 2,474 1,832 Warrants for common stock 4,085 1,963 1,963 1,963 Total common stock equivalents 6,559 3,795 4,437 3,795

Segment Disclosures (Tables)

Segment Disclosures (Tables)	9 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Schedule of Segment Reporting Information	Segment reporting information is as follows: Medical Industrial Engineering Devices Sales Services Total Three months ended September 30, 2016 Revenue $ 1,089 $ 406 $ 101 $ 1,596 Cost of revenue 833 290 70 1,193 Gross profit $ 256 $ 116 $ 31 $ 403 Three months ended September 30, 2015 Revenue $ 1,095 $ - $ 1,820 $ 2,915 Cost of revenue 1,095 - 1,352 2,447 Gross profit $ - $ - $ 468 $ 468 Nine months ended September 30, 2016 Revenue $ 10,321 $ 682 $ 631 $ 11,634 Cost of revenue 8,543 535 452 9,530 Gross profit $ 1,778 $ 147 $ 179 $ 2,104 Nine months ended September 30, 2015 Revenue $ 3,128 $ - $ 3,590 $ 6,718 Cost of revenue 2,863 - 2,482 5,345 Gross profit $ 265 $ - $ 1,108 $ 1,373
Schedule of Geographic Information	Geographic information for revenue based on location of customer is as follows: Three months ended September 30, Nine months ended September 30, 2016 2015 2016 2015 North America $ 1,243 $ 2,379 $ 6,940 $ 5,272 All Other 353 536 4,694 1,446 $ 1,596 $ 2,915 $ 11,634 $ 6,718

Organization (Details Textual)

Organization (Details Textual) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Organization [Line Items]
Retained Earnings (Accumulated Deficit), Total	$ (109,284)		$ (91,390)
Cash and Cash Equivalents, at Carrying Value	12,800	$ 11,238	$ 19,552	$ 25,190
Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total	$ (20,555)	$ (13,082)

Basis of Presentation and Sum36

Basis of Presentation and Summary of Significant Accounting Policies and Estimates (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Significant Accounting Policies [Line Items]
Reduction In Net Loss Attributable To Common Stock Holders			$ 2,358
Medical Device [Member]
Significant Accounting Policies [Line Items]
Reduction In Net Loss Attributable To Common Stock Holders			2,358
Deferred Revenue, Revenue Recognized					$ 6,517
Cost of Revenue					$ 4,159
Product Liability Accrual, Component Amount	$ 212		212
Customer Advances and Deposits, Current, Total	$ 911		$ 911
Minimum [Member] | Medical Device [Member]
Significant Accounting Policies [Line Items]
Revenue Maintenance Contractual Agreement Term			1 year
Maximum [Member] | Medical Device [Member]
Significant Accounting Policies [Line Items]
Revenue Maintenance Contractual Agreement Term			4 years
Accounts Receivable [Member]
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage			13.00%
Sales Revenue, Net [Member]
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage	15.00%		10.00%
Customer One [Member] | Accounts Receivable [Member]
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage			10.00%		10.00%
Customer One [Member] | Sales Revenue, Net [Member]
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage	10.00%	48.00%		33.00%

Accumulated Other Comprehensi37

Accumulated Other Comprehensive Loss (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2016USD ($)
Balance at December 31, 2015	$ (1)
Other comprehensive loss before reclassification	(6)
Amounts reclassified from accumulated other comprehensive loss	0
Net current period other comprehensive loss	(6)
Balance at September 30, 2016	$ (7)

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Liabilities:
Warrant liability	$ (6,165)	$ (9,195)
Fair Value, Measurements, Recurring [Member]
Liabilities:
Warrant liability	(6,165)	(9,195)
Contingent consideration liability	(768)	(768)
Quoted Prices in Active Markets for Identical Items Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Liabilities:
Warrant liability	0	0
Contingent consideration liability	0	0
Significant Other Observable Inputs Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Liabilities:
Warrant liability	0	0
Contingent consideration liability	0	0
Significant Unobservable Inputs Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Liabilities:
Warrant liability	(6,165)	(9,195)
Contingent consideration liability	$ (768)	$ (768)

Fair Value Measurements (Deta39

Fair Value Measurements (Details 1) $ in Thousands	9 Months Ended
	Sep. 30, 2016USD ($)
Derivative Financial Instruments, Liabilities [Member]
Derivative [Line Items]
Balance at December 31, 2015	$ (9,195)
Gain on decrease in fair value of warrants issued with 2015 financing	3,030
Balance at September 30, 2016	(6,165)
Contingent Consideration [Member]
Derivative [Line Items]
Balance at December 31, 2015	(768)
Gain on decrease in fair value of warrants issued with 2015 financing	0
Balance at September 30, 2016	$ (768)

Inventories, net (Details)

Inventories, net (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Raw materials	$ 1,380	$ 783
Work in process	432	336
Finished goods	151	19
Inventory, Gross	1,963	1,138
Less: inventory reserve	(48)	(82)
Inventories, net	$ 1,915	$ 1,056

Deferred Revenues (Details)

Deferred Revenues (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Deferred Revenue Arrangement [Line Items]
Deferred rental income	$ 74	$ 71
Total deferred revenues	1,920	8,573
Less current portion	(1,098)	(3,960)
Deferred revenues, non-current	822	4,613
Deferred medical device unit costs	92	4,590
Less current portion	(92)	(2,088)
Deferred cost of revenue, non-current	0	2,502
Customer deposits and advances [Member]
Deferred Revenue Arrangement [Line Items]
Total deferred revenues	60	48
Deferred medical device revenues [Member]
Deferred Revenue Arrangement [Line Items]
Total deferred revenues	301	7,388
Deferred extended maintenance and support [Member]
Deferred Revenue Arrangement [Line Items]
Total deferred revenues	$ 1,485	$ 1,066

Deferred Revenues (Details Text

Deferred Revenues (Details Textual) - Medical Device [Member] - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Deferred Revenue Arrangement [Line Items]
Deferred Revenue, Revenue Recognized		$ 6,517
Cost of Revenue		$ 4,159
Maximum [Member]
Deferred Revenue Arrangement [Line Items]
Revenue Maintenance Contractual Agreement Term	4 years
Minimum [Member]
Deferred Revenue Arrangement [Line Items]
Revenue Maintenance Contractual Agreement Term	1 year

Intangible Assets (Details)

Intangible Assets (Details) $ in Thousands	Sep. 30, 2016USD ($)
Indefinite-lived Intangible Assets [Line Items]
Cost	$ 1,610
Accumulated Amortization	(448)
Net	1,162
Developed Technology Rights [Member]
Indefinite-lived Intangible Assets [Line Items]
Cost	1,160
Accumulated Amortization	(323)
Net	837
Customer Relationships [Member]
Indefinite-lived Intangible Assets [Line Items]
Cost	70
Accumulated Amortization	(19)
Net	51
Customer Trade Name [Member]
Indefinite-lived Intangible Assets [Line Items]
Cost	380
Accumulated Amortization	(106)
Net	$ 274

Intangible Assets (Details Text

Intangible Assets (Details Textual) - USD ($) $ in Thousands	Dec. 01, 2015	Sep. 30, 2016	Dec. 31, 2015
Indefinite-lived Intangible Assets [Line Items]
Business Combination, Contingent Consideration, Liability		$ 768	$ 768
Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year		135
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months		537
Finite-Lived Intangible Assets, Amortization Expense, Year Two		490
Equipois, LLC [Member]
Indefinite-lived Intangible Assets [Line Items]
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	$ 1,071
Business Combination, Contingent Consideration, Liability	$ 768
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total		$ 1,610
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life		3 years

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Accrued Liabilities [Line Items]
Salaries, benefits and related expenses	$ 1,988	$ 1,464
Maintenance	579	0
Warranty expense	186	0
Professional fees	137	257
Other	92	164
Total	$ 2,982	$ 1,885

Maintenance and Warranty (Detai

Maintenance and Warranty (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2016
Beginning Balance	$ 0
Additions for estimated future expense	1,267
Incurred costs	(493)
Closing Balance	774
Current portion		$ 765
Long-term portion		9
Total	0	774
Maintenance [Member]
Beginning Balance	0
Additions for estimated future expense	911
Incurred costs	(332)
Closing Balance	579
Current portion		579
Long-term portion		0
Total	0	579
Warranty [Member]
Beginning Balance	0
Additions for estimated future expense	356
Incurred costs	(161)
Closing Balance	195
Current portion		186
Long-term portion		9
Total	$ 0	$ 195

Maintenance and Warranty (Det47

Maintenance and Warranty (Details Textual) $ in Thousands	9 Months Ended
	Sep. 30, 2016USD ($)
Cost of Property Repairs and Maintenance	$ 911

Lease and Note Obligations (Det

Lease and Note Obligations (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
2016 - remainder	$ 23
2,017	60
2,018	37
2,019	37
2,020	22
Thereafter	0
Total minimum payments	179
Less interest	(13)
Present value minimum payments	166
Less current portion	(67)	$ (80)
Long-term portion	99
Capital Lease Obligations [Member]
Debt Instrument [Line Items]
2016 - remainder	11
2,017	40
2,018	37
2,019	37
2,020	22
Thereafter	0
Total minimum payments	147
Less interest	(12)
Present value minimum payments	135
Less current portion	(36)
Long-term portion	99
Lease hold Improvement Note [Member]
Debt Instrument [Line Items]
2016 - remainder	12
2,017	20
2,018	0
2,019	0
2,020	0
Thereafter	0
Total minimum payments	32
Less interest	(1)
Present value minimum payments	31
Less current portion	(31)
Long-term portion	0
Operating Lease [Member]
Debt Instrument [Line Items]
2016 - remainder	116
2,017	461
2,018	483
2,019	494
2,020	504
Thereafter	610
Total minimum payments	$ 2,668

Lease and Note Obligations (D49

Lease and Note Obligations (Details Textual) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		9 Months Ended
	Nov. 30, 2016	Nov. 30, 2011	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Debt Instrument [Line Items]
Operating Leases, Rent Expense, Net, Total			$ 101	$ 86	$ 299	$ 258
Lease Expiration Date	May 31, 2022	May 31, 2017
Capital Lease Obligations [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross			$ 166		$ 166
Debt Instrument, Interest Rate, Stated Percentage			4.70%		4.70%
Debt Instrument, Maturity Date					Jul. 1, 2020
Debt Instrument Minimum Monthly Payments					$ 3
Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross			$ 200		$ 200
Debt Instrument, Interest Rate, Stated Percentage			7.00%		7.00%
Debt Instrument, Maturity Date					May 31, 2017
Debt Instrument Minimum Monthly Payments					$ 4

Capitalization and Equity Str50

Capitalization and Equity Structure (Details) - $ / shares shares in Thousands	9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Schedule of Capitalization, Equity [Line Items]
Merger/PPO Warrant Shares Outstanding	4,085	4,085
December 2015 warrants [Member]
Schedule of Capitalization, Equity [Line Items]
Exercise price	$ 3.74
Warrant term	5 years
Merger/PPO Warrant Shares Outstanding	2,122	2,122
Pre 2014 Warrants [Member]
Schedule of Capitalization, Equity [Line Items]
Exercise price	$ 9.66
Merger/PPO Warrant Shares Outstanding	88	88
2014 PPO and Merger [Member] | Placement agent warrants [Member]
Schedule of Capitalization, Equity [Line Items]
Exercise price	$ 7
Warrant term	5 years
Merger/PPO Warrant Shares Outstanding	426	426
2014 PPO and Merger [Member] | Bridge warrants [Member]
Schedule of Capitalization, Equity [Line Items]
Exercise price	$ 7
Warrant term	3 years
Merger/PPO Warrant Shares Outstanding	371	371
2014 PPO and Merger [Member] | PPO warrants [Member]
Schedule of Capitalization, Equity [Line Items]
Exercise price	$ 14
Warrant term	5 years
Merger/PPO Warrant Shares Outstanding	1,078	1,078

Capitalization and Equity Str51

Capitalization and Equity Structure (Details 1) - Binomial Lattice Option Pricing Model [Member] - Warrant [Member]	9 Months Ended
	Sep. 30, 2016$ / shares
Schedule of Capitalization, Equity [Line Items]
Current share price	$ 4.70
Conversion price	$ 3.74
Risk-free interest rate	1.04%
Term (years)	4 years 2 months 23 days
Volatility of stock	75.00%

Capitalization and Equity Str52

Capitalization and Equity Structure (Details Textual) $ / shares in Units, $ in Thousands	1 Months Ended			3 Months Ended	9 Months Ended		12 Months Ended
	Oct. 30, 2016USD ($)$ / sharesshares	Aug. 31, 2016shares	Aug. 12, 2016USD ($)$ / sharesshares	Sep. 30, 2016USD ($)shares	Sep. 30, 2016USD ($)shares	Sep. 30, 2015USD ($)	Dec. 31, 2015USD ($)$ / sharesshares
Class of Stock [Line Items]
Common Stock, Shares Authorized				71,429,000	71,429,000		71,429,000
Preferred Stock, Shares Authorized				10,000,000	10,000,000		10,000,000
Common Stock, Shares, Issued				21,393,000	21,393,000		15,027,000
Preferred Stock, Shares Outstanding		3,000		0	0		13,000
Stock Issued During Period, Shares, New Issues							15,000
Fair Value Adjustment of Warrants | $				$ 1,620	$ 3,030
Warrants Not Settleable in Cash, Fair Value Disclosure | $							$ 9,195
Conversion of Stock, Shares Converted		921,000		1,000	10,000
Conversion of Stock, Shares Issued		267		60,000	1,389,000
Preferred Stock Convertible Conversion Price				7.07	7.07
Proceeds from Issuance of Common Stock | $					$ 14,694	$ 0
Stockholders' Equity, Reverse Stock Split					1-for-7 reverse split
Subsequent Event [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues	488,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 3.74
Proceeds from Issuance of Common Stock | $	$ 1,825
Class of Warrant or Right, Number Of Warrants Exercised	488,000
Over-Allotment Option [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues			267,000
Proceeds from Issuance of Common Stock | $			$ 998
2016 Equity Offering [Member]
Class of Stock [Line Items]
Conversion of Stock, Shares Issued			267				141
2016 Equity Offering [Member] | Common Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues			3,750,000
Sale of Stock, Price Per Share | $ / shares			$ 4
Proceeds from Issuance of Common Stock | $			$ 13,696
Warrant [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							2,122,000
Warrants Term							5 years
Warrant [Member] | Minimum [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares							$ 3.74
Warrant [Member] | Maximum [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares							$ 8.75
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							2,122,000
Gross Proceeds from Preferred Stock and Warrants | $							$ 15,000
Conversion of Stock, Shares Converted				3,000	3,000
Conversion of Stock, Shares Issued				921,000	921,000
Preferred Stock Convertible Conversion Price				3.74	3.74
Series A Preferred Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Preferred Stock Convertible Conversion Price		3.74
Series A Preferred Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Preferred Stock Convertible Conversion Price		7.07
Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Amortization of Financing Costs and Discounts, Total | $				$ 3,016	$ 10,345

Stock-based Compensation (Detai

Stock-based Compensation (Details) - 2014 Plan [Member] $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended
	Sep. 30, 2016USD ($)$ / sharesshares
Options Outstanding
Stock Awards, Balance	1,963
Stock Awards, Options granted	776
Stock Awards, Options exercised	(30)
Stock Awards, Options forfeited	(207)
Stock Awards, Options cancelled	(28)
Stock Awards, Balance	2,474
Stock Awards, Vested and expected to vest	2,294
Stock Awards, Exercisable	1,180
Weighted-Average Exercise Price, Balance | $ / shares	$ 7.09
Weighted-Average Exercise Price, Options granted | $ / shares	5.44
Weighted-Average Exercise Price, Options exercised | $ / shares	2.4
Weighted-Average Exercise Price, Options forfeited | $ / shares	8.11
Weighted-Average Exercise Price, Options cancelled | $ / shares	9.58
Weighted-Average Exercise Price, Balance | $ / shares	$ 6.51
Weighted-Average Remaining Contractual Life (Years), Balance	7 years 7 months 28 days
Weighted-Average Remaining Contractual Life (Years), Vested and expected to vest	7 years 6 months 11 days
Weighted-Average Remaining Contractual Life (Years), Exercisable	6 years 11 days
Aggregate Intrinsic Value, Balance | $	$ 1,322
Aggregate Intrinsic Value, Vested and expected to vest | $	1,279
Aggregate Intrinsic Value, Exercisable | $	$ 1,089

Stock-based Compensation (Det54

Stock-based Compensation (Details 1)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%	0.00%	0.00%
Risk-free interest rate		1.68%
Risk-free interest rate, minimum	1.25%		1.24%	1.41%
Risk-free interest rate, maximum	1.26%		1.78%	2.50%
Expected term (in years)	6 years	6 years
Volatility	80.00%	75.00%
Volatility, minimum			77.00%	73.00%
Volatility, maximum			80.00%	75.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)			5 years	6 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)			10 years	10 years

Stock-based Compensation (Det55

Stock-based Compensation (Details 2) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	$ 451	$ 467	$ 2,552	$ 1,259
Sales and marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	103	147	541	440
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	127	133	499	295
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	$ 221	$ 187	$ 1,512	$ 524

Stock-based Compensation (Det56

Stock-based Compensation (Details Textual) - USD ($) shares in Thousands, $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Total	$ 2,552	$ 1,259
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Total	59
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Total	774
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 5,360
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 9 months 18 days
Equity Incentive Plan 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	3,714
Common Stock, Capital Shares Reserved for Future Issuance	965

Commitments and Contingencies (

Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands	9 Months Ended	13 Months Ended
	Sep. 30, 2016	Dec. 31, 2016
Future minimum annual royalties:
Contractual Obligation, Due in Next Fiscal Year	$ 50
Scenario, Forecast [Member]
Future minimum annual royalties:
Supply Agreement ,Minimum Annual Price		$ 157
Royalty Agreement Terms [Member]
Future minimum annual royalties:
Contractual Obligation, Due in Next Fiscal Year	$ 50
Royalty Agreement Terms [Member] | Net sales [Member]
Future minimum annual royalties:
Royalty Percentage	1.00%
Royalty Agreement Terms [Member] | License fees [Member]
Future minimum annual royalties:
Royalty Percentage	21.00%
Royalty Agreement Terms [Member] | Sub-licensee net sales [Member]
Future minimum annual royalties:
Royalty Percentage	1.00%

Net Loss Per Share (Details)

Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Numerator:
Net loss applicable to common stockholders, Basic	$ (11,494)	$ (5,185)	$ (28,239)	$ (14,945)
Adjustment for revaluation of warrant liability	0	0	(3,030)	0
Net loss applicable to common stockholders, Diluted	$ (11,494)	$ (5,185)	$ (31,269)	$ (14,945)
Denominator
Weighted-average number of shares, basic	19,005	14,606	16,888	14,578
Effect of dilutive warrants	0	0	707	0
Weighted-average numbers of shares, diluted	19,005	14,606	17,595	14,578
Net loss per share, basic	$ (0.60)	$ (0.35)	$ (1.67)	$ (1.03)
Net loss per share, diluted	$ (0.60)	$ (0.35)	$ (1.78)	$ (1.03)

Net Loss Per Share (Details 1)

Net Loss Per Share (Details 1) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	6,559	3,795	4,437	3,795
Options to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	2,474	1,832	2,474	1,832
Warrants for common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	4,085	1,963	1,963	1,963

Net Loss Per Share (Details Tex

Net Loss Per Share (Details Textual) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2016USD ($)$ / shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Reduction In Net Loss Attributable To Common Stock Holders | $	$ 2,358
Reduction In Net Loss Per Share Attributable To Common Stock Holders | $ / shares	$ 0.14

Segment Disclosures (Details)

Segment Disclosures (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Segment Reporting Information [Line Items]
Revenue	$ 1,596	$ 2,915	$ 11,634	$ 6,718
Cost of revenue	1,193	2,447	9,530	5,345
Gross profit	403	468	2,104	1,373
Medical Devices [Member]
Segment Reporting Information [Line Items]
Revenue	1,089	1,095	10,321	3,128
Cost of revenue	833	1,095	8,543	2,863
Gross profit	256	0	1,778	265
Industrial Sales [Member]
Segment Reporting Information [Line Items]
Revenue	406	0	682	0
Cost of revenue	290	0	535	0
Gross profit	116	0	147	0
Engineering Services [Member]
Segment Reporting Information [Line Items]
Revenue	101	1,820	631	3,590
Cost of revenue	70	1,352	452	2,482
Gross profit	$ 31	$ 468	$ 179	$ 1,108

Segment Disclosures (Details 1)

Segment Disclosures (Details 1) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Segment Reporting Information [Line Items]
Revenue	$ 1,596	$ 2,915	$ 11,634	$ 6,718
North America [Member]
Segment Reporting Information [Line Items]
Revenue	1,243	2,379	6,940	5,272
All Other [Member]
Segment Reporting Information [Line Items]
Revenue	$ 353	$ 536	$ 4,694	$ 1,446